Replies to post #141259 on Biotech Values

[biomaven0]

The company is following the Velcade path almost step by step

The big difference is that the unmet need is significantly less now.
If I were making the decision I would approve it - hard for me to see much in the way of harm and patients would benefit. Worst case is the drug is on the market for a year or two and gets withdrawn if the Phase III's somehow fail.

Peter